No Clinically Significant Drug Interactions Between Testosterone and Keppra/Lamotrigine
There are no documented pharmacokinetic or pharmacodynamic interactions between supplemental testosterone and either levetiracetam (Keppra) or lamotrigine in patients taking these antiepileptic medications. You can safely prescribe testosterone supplementation to patients on this antiepileptic regimen without dose adjustments.
Pharmacokinetic Evidence
Levetiracetam (Keppra) Interaction Profile
Levetiracetam has an exceptionally clean drug interaction profile. The FDA label explicitly states that levetiracetam and its metabolites are neither inhibitors of nor substrates for cytochrome P450 enzymes, epoxide hydrolase, or UDP-glucuronidation enzymes 1. This means levetiracetam does not affect the metabolism of other medications, including testosterone.
Key pharmacokinetic facts:
- Levetiracetam circulates largely unbound (<10% protein binding), making protein-binding displacement interactions unlikely 1
- In vitro studies confirm no inhibitory effects on 11 different drug-metabolizing enzyme activities at concentrations well above therapeutic levels 2
- Multiple studies demonstrate levetiracetam does not influence plasma concentrations of other antiepileptic drugs including carbamazepine, valproate, topiramate, or lamotrigine 1, 3
- Levetiracetam is classified as a non-enzyme-inducing antiepileptic drug 4, 5, 6
Lamotrigine Interaction Profile
Lamotrigine similarly lacks significant enzyme-inducing properties. Guidelines specifically identify lamotrigine as a preferred first-choice antiepileptic because of its efficacy and overall good tolerability, with minimal drug interaction potential 5.
Evidence shows:
- Lamotrigine is a weak inducer of UGTs at most, with no significant CYP3A4 induction 7
- It does not alter concentrations of oral contraceptives or affect 6β-hydroxycortisol excretion 7
- Lamotrigine is metabolized primarily via glucuronidation, not through pathways that would interact with testosterone 8
Testosterone Metabolism Considerations
Testosterone is metabolized primarily through:
- CYP3A4 (major pathway)
- 5α-reductase conversion to dihydrotestosterone
- Aromatase conversion to estradiol
Since neither levetiracetam nor lamotrigine affects CYP3A4 activity or other testosterone metabolic pathways, no interaction is expected in either direction.
Clinical Management
No dose adjustments are required for testosterone, levetiracetam, or lamotrigine when used together. However, monitor for:
- Seizure control: Ensure antiepileptic medications remain effective, though testosterone itself is not known to lower seizure threshold
- Testosterone efficacy: Standard monitoring of testosterone levels and clinical response applies
- Behavioral changes: Both levetiracetam and testosterone can independently affect mood; levetiracetam may cause psychiatric side-effects including aggression, agitation, and irritability 1
Important Caveats
This clean interaction profile contrasts sharply with enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital) which should be avoided as they significantly induce CYP3A4 and would accelerate testosterone metabolism 4, 5. Your patient's regimen of levetiracetam and lamotrigine represents an optimal choice from an interaction standpoint.
The absence of interaction data in the literature reflects the lack of clinically significant interactions rather than insufficient study—both medications have been extensively evaluated for drug interactions with negative findings 1, 2, 7.